Ziff Davis, Inc. (ZD)

Verve Therapeutics Stock Forecast

Stock Price Forecast

The 6 analysts that cover Verve Therapeutics stock have a consensus rating of "Hold" and an average price target of $49.67, which forecasts a 31.79% increase in the stock price over the next year. The lowest target is $33 and the highest is $95.

Price Target: $49.67 (+31.79%)

Analyst Consensus: Hold

Target	Low	Average	Median	High
Price	$33	$49.67	$45	$95
Change	-12.44%	+31.79%	+19.40%	+152.06%

* Price targets were last updated on May 13, 2025.

Analyst Ratings

The average analyst rating for Verve Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.

Recommendation Trends

Rating	Mar '25	Apr '25	May '25	Jun '25	Jul '25	Aug '25
Strong Buy	0	0	0	0	0	0
Buy	3	2	2	2	2	2
Hold	4	4	4	4	4	4
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	7	6	6	6	6	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Ross Sandler Barclays	Barclays	Hold Maintains $48 → $34	Hold	Maintains	$48 → $34	-9.79%	May 13, 2025
Shyam Patil Susquehanna	Susquehanna	Buy Maintains $80 → $45	Buy	Maintains	$80 → $45	+19.40%	May 12, 2025
Ygal Arounian Citigroup	Citigroup	Hold Maintains $52 → $35	Hold	Maintains	$52 → $35	-7.14%	Apr 25, 2025
Cory Carpenter JP Morgan	JP Morgan	Buy → Hold Downgrades $60 → $33	Buy → Hold	Downgrades	$60 → $33	-12.44%	Apr 22, 2025
Chris Kuntarich UBS	UBS	Hold Maintains $65 → $56	Hold	Maintains	$65 → $56	+48.58%	Feb 26, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

1.51B

Increased by 7.37%

from 1.40B

Revenue Next Year

1.56B

Increased by 3.65%

from 1.51B

EPS This Year

6.98

Increased by 392.14%

from 1.42

EPS Next Year

7.33

Increased by 4.97%

from 6.98

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	1.16B	1.42B	1.39B	1.36B	1.40B	1.51B	1.56B	1.61B
Revenue Growth	10.32%	22.26%	-1.82%	-1.94%	2.76%	7.37%	3.65%	2.95%
EPS	3.20	10.37	1.35	0.89	1.42	6.98	7.33	7.77
EPS Growth	-28.24%	224.16%	-86.95%	-34.25%	59.34%	392.14%	4.97%	6.09%
Forward PE	-	-	-	-	-	5.40	5.14	4.85
No. Analysts	-	-	-	-	-	9	10	7

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	1.5B	1.6B	1.7B
Avg	1.5B	1.6B	1.6B
Low	1.4B	1.5B	1.5B

Revenue Growth

Revenue Growth	2025	2026	2027
High	10.3%	7.8%	6.9%
Avg	7.4%	3.7%	2.9%
Low	1.2%	-3.5%	-5.1%

EPS Forecast

EPS	2025	2026	2027
High	7.33	7.75	8.06
Avg	6.98	7.33	7.77
Low	6.40	6.40	7.10

EPS Growth

EPS Growth	2025	2026	2027
High	416.8%	11.0%	10.0%
Avg	392.1%	5.0%	6.1%
Low	351.2%	-8.3%	-3.2%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.